{
    "clinical_study": {
        "@rank": "82225", 
        "arm_group": {
            "arm_group_label": "SOF+PEG+RBV", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive SOF+PEG+RBV for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of\n      sofosbuvir (SOF) in combination with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV)\n      administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus\n      (HCV) infection who have previously failed prior treatment with an interferon-based regimen."
        }, 
        "brief_title": "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infection with HCV GT 2 or 3\n\n          -  Cirrhosis determination\n\n          -  Subject is treatment-experienced\n\n          -  Screening laboratory values within defined thresholds\n\n          -  Subject has not been treated with any investigational drug or device within 30 days\n             of the Screening visit\n\n          -  Use of highly effective contraception methods if female of childbearing potential or\n             sexually active male\n\n        Exclusion Criteria:\n\n          -  Prior exposure to an direct-acting antiviral targeting the HCV NS5B polymerase\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  Current or prior history of clinical hepatic decompensation\n\n          -  History of clinically-significant illness or any other major medical disorder that\n             may interfere with subject treatment, assessment or compliance with the protocol\n\n          -  Excessive alcohol ingestion or significant drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "Yes", 
        "id_info": {
            "nct_id": "NCT01808248", 
            "org_study_id": "GS-US-334-0151"
        }, 
        "intervention": [
            {
                "arm_group_label": "SOF+PEG+RBV", 
                "description": "Sofosbuvir (SOF) 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "Sovaldi\u2122"
                ]
            }, 
            {
                "arm_group_label": "SOF+PEG+RBV", 
                "description": "Peginterferon alfa-2a (PEG) 180 \u03bcg administered once weekly by subcutaneous injection", 
                "intervention_name": "PEG", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SOF+PEG+RBV", 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Anti-Infective Agents", 
                "Ribavirin", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV genotype 2 (GT-2)", 
            "HCV genotype 3 (GT-3)", 
            "HCV", 
            "Sustained Virologic Response", 
            "Direct Acting Antiviral", 
            "Combination Therapy", 
            "Treatment-Na\u00efve", 
            "GS-7977", 
            "Ribavirin", 
            "RBV", 
            "Peginterferon Alfa 2a", 
            "PEG", 
            "Additional relevant MeSH terms:", 
            "Hepatitis", 
            "Hepatitis A", 
            "Hepatitis, Chronic", 
            "Hepatitis C", 
            "Hepatitis C, Chronic", 
            "Liver Diseases", 
            "Digestive System Diseases", 
            "Hepatitis, Viral, Human", 
            "Virus Diseases", 
            "Enterovirus Infections", 
            "Picornaviridae Infections", 
            "RNA Virus Infections", 
            "Flaviviridae Infections", 
            "Peginterferon alfa-2a", 
            "Interferon-alpha", 
            "Antiviral Agents", 
            "Anti-Infective Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Antimetabolites", 
            "Molecular Mechanisms of Pharmacological Action", 
            "Immunologic Factors", 
            "Physiological Effects of Drugs"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "link": [
            {
                "description": "Medicine Plus", 
                "url": "http://www.nlm.nih.gov/medlineplus/"
            }, 
            {
                "description": "Hepatitis", 
                "url": "http://www.nlm.nih.gov/medlineplus/hepatitis.html"
            }, 
            {
                "description": "Hepatitis A", 
                "url": "http://www.nlm.nih.gov/medlineplus/hepatitisa.html"
            }, 
            {
                "description": "Hepatitis C", 
                "url": "http://www.nlm.nih.gov/medlineplus/hepatitisc.html"
            }, 
            {
                "description": "Drug Information avialble for:", 
                "url": "http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp"
            }, 
            {
                "description": "Ribavirin", 
                "url": "http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0036791045&QV1=RIBAVIRIN"
            }, 
            {
                "description": "PEGINTERFERON ALFA-2A", 
                "url": "http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0198153514&QV1=PEGINTERFERON+ALFA-2A"
            }, 
            {
                "description": "U.S. FDA Resources", 
                "url": "http://clinicaltrials.gov/ct2/info/fdalinks"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78215"
                }, 
                "name": "Alamo Medical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-Label Study of Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Rob Hyland", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study medication.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Week 12"
            }, 
            {
                "description": "Safety data will be summarized by treatment arm.", 
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808248"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < LLOQ at 4 and 24 weeks following the last dose of study medication, respectively.", 
                "measure": "Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment Weeks 4 and 24"
            }, 
            {
                "description": "Virologic failure will be measured by incidence of on-treatment failure and viral relapse.\nOn-treatment virologic failures\nHCV RNA \u2265 LLOQ after having previously had HCV RNA <LLOQ while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment) or last available on-treatment measurement with no subsequent follow-up values (i.e., breakthrough)\n>1 log10 IU/ml increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment) or last available on-treatment measurement with no subsequent follow-up values (i.e., rebound)\nHCV RNA persistently \u2265LLOQ through 8 weeks of treatment (i.e., non-response)\nRelapse\nHCV RNA \u2265 LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement", 
                "measure": "Proportion of participants with virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to post-treatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}